Literature DB >> 20390333

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

Roos L Oostendorp1, T Buckle, G Lambert, J S Garrigue, J H Beijnen, J H M Schellens, O van Tellingen.   

Abstract

The anticancer drug paclitaxel is formulated for i.v. administration in a mixture of Cremophor EL and ethanol.Its oral bioavailability is very low due to the action of P-glycoproteinin the gut wall and CYP450 in gut wall and liver.However, proof-of-concept studies using the i.v. formulation diluted in drinking water have demonstrated the feasibility of the oral route as an alternative when given in combination with inhibitors of P-glycoprotein and CYP450. Because of the unacceptable pharmaceutical properties of the drinking solution, a better formulation for oral application is needed.We have evaluated the suitability of various self-micro emulsifying oily formulations (SMEOF's) of paclitaxel for oral application using wild-type and P-glycoprotein knockout mice and cyclosporin A (CsA) as P-glycoprotein and CYP450 inhibitor. The oral bioavailability of paclitaxel in all SMEOF's without concomitant CsA was low in wild-type mice, showing that this vehicle does not enhance intestinal uptake by itself.Paclitaxel (10 mg/kg) in SMEOF#3 given with CsA resulted in plasma levels that were comparable to the Cremophor ELethanol containing drinking solution plus CsA. Whereas the AUC increased linearly with the oral paclitaxel dose in P-glycoprotein knockout mice, it increased less than proportional in wild-type mice given with CsA. In both strains more unchanged paclitaxel was recovered in the feces at higher doses. This observation most likely reflects more profound precipitation of paclitaxel within the gastro-intestinal tract at higher doses. The resulting absolute reduction in absorption of paclitaxel from the gut was possibly concealed by partial saturation of first-pass metabolism when P-glycoprotein was absent. In conclusion, SMEOF's maybe a useful vehicle for oral delivery of paclitaxel in combination with CsA, although the physical stability within the gastro-intestinal tract remains a critical issue, especially when applied at higher dose levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20390333      PMCID: PMC3160553          DOI: 10.1007/s10637-010-9421-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  26 in total

Review 1.  Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs.

Authors:  T Gershanik; S Benita
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

2.  The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers.

Authors:  T Chang; L Z Benet; M F Hebert
Journal:  Clin Pharmacol Ther       Date:  1996-03       Impact factor: 6.875

3.  Phase I and pharmacokinetic study of oral paclitaxel.

Authors:  M M Malingré; J M Terwogt; J H Beijnen; H Rosing; F J Koopman; O van Tellingen; K Duchin; W W Huinink; M Swart; J Lieverst; J H Schellens
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

Authors:  C M F Kruijtzer; J H M Schellens; J Mezger; M E Scheulen; U Keilholz; J H Beijnen; H Rosing; R A A Mathôt; S Marcus; H van Tinteren; P Baas
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

5.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Variability in human cytochrome P450 paclitaxel metabolism.

Authors:  D S Sonnichsen; Q Liu; E G Schuetz; J D Schuetz; A Pappo; M V Relling
Journal:  J Pharmacol Exp Ther       Date:  1995-11       Impact factor: 4.030

7.  Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

Authors:  C M F Kruijtzer; H Boot; J H Beijnen; H L Lochs; F X Parnis; A S T Planting; J M G Pelgrims; R Williams; R A A Mathôt; H Rosing; M E Schot; H Van Tinteren; J H M Schellens
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

Review 8.  Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.

Authors:  E K Rowinsky; M Wright; B Monsarrat; R C Donehower
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

9.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Authors:  J van Asperen; O van Tellingen; A Sparreboom; A H Schinkel; P Borst; W J Nooijen; J H Beijnen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Authors:  M M Malingré; J H Schellens; O Van Tellingen; M Ouwehand; H A Bardelmeijer; H Rosing; F J Koopman; M E Schot; W W Ten Bokkel Huinink; J H Beijnen
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

View more
  2 in total

Review 1.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

2.  Preparation of Polyethylene Glycol-Ginsenoside Rh1 and Rh2 Conjugates and Their Efficacy against Lung Cancer and Inflammation.

Authors:  Ramya Mathiyalagan; Chao Wang; Yeon Ju Kim; Verónica Castro-Aceituno; Sungeun Ahn; Sathiyamoorthy Subramaniyam; Shakina Yesmin Simu; Zuly Elizabeth Jiménez-Pérez; Deok Chun Yang; Seok-Kyu Jung
Journal:  Molecules       Date:  2019-11-29       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.